Automated, AI-based insulin management in the works

People with Type 1 diabetes may soon be able to count on an algorithm to keep their blood sugar levels within a healthy range, as research to tap the power of Big Data for automating personalized glucose monitoring and insulin delivery is underway at Rensselaer Polytechnic Institute in Troy, N.Y.

The project is getting funded by JDRF, formerly known as the Juvenile Diabetes Research Foundation, and it’s being led by Rensselaer chemical and biological engineer Wayne Bequette, PhD.

Much of the data for training the AI will come from thousands of continuous glucose monitors and insulin pumps presently in use, according to an announcement from the school.

The nonprofit Tidepool is making data available after de-identifying patients from whom it’s drawn through its Tidepool Big Data Donation Project.

Another aim of the research is to leverage AI for showing whether signals from glucose monitors is trustworthy.

“If we look at hundreds of people we can say, ‘Oh, certain problems occur more often in this age group, this type of population or with this particular type of sensor,’” Bequette says. “If, for example, you find that it’s more likely that people 8 to 12 years old have these types of irregularities, then you can account for that in your algorithm and provide more personalized control while reducing burden.”

Rensselaer notes Bequette has been interested in countering diabetes since his sister was diagnosed with the condition in the ’70s. His contributions to the science include developing a closed-loop artificial pancreas that automatically adjusts an insulin infusion pump based on signals from a continuous glucose monitor.

For the new AI-based project, Bequette will continue a long-running collaboration with colleagues at the Icahn School of Medicine and the University of Colorado.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”